Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Multiple System Atrophy (MSA) · Healthy Adult · Parkinson Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute for Neurodegenerative Disorders and XingImaging, LLC, New Haven, Connecticut, United States
Contact: Study coordinator (Mackenzee George) · mgeorge@xingimaging.com · 475-318-8250 (24 hours)
Contact: Principal Investigator (Neha Prakash, MBBS)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers

Healthy Adult

Abroad (travel likely)RecruitingEARLY_PHASE1

New Haven, United States

AI-Enhanced Optimization of Acute Levodopa Challenge Test

Vascular Parkinsonism · Drug-induced Parkinsonism · Corticobasal Degeneration (CBD)

Abroad (travel likely)Recruiting

Beijing, China

A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA

Multiple System Atrophy (MSA) · Parkinson's Disease (PD)

Abroad (travel likely)RecruitingPHASE1

Wuxi, China · Shanghai, China

[18F]ACI-15916 PET in α-synucleinopathies

Parkinson's Disease (PD) · Multiple System Atrophy (MSA) · Dementia With Lewy Bodies (DLB)

Abroad (travel likely)RecruitingEARLY_PHASE1

Solna, Sweden